


FDA approves Dovato for teens living with HIV

April 11 2024, by Lori Solomon



The U.S. Food and Drug Administration has approved Dovato (dolutegravir/lamivudine) for adolescents living with HIV.

The approval is for the treatment of HIV-1 infection in adolescents aged 12 years and older (weighing ≥ 25 kg) with no antiretroviral (ARV)

treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA

Citation: FDA approves Dovato for teens living with HIV (2024, April 11) retrieved 2 May 2024 from <https://medicalxpress.com/news/2024-04-fda-dovato-teens-hiv.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.